Keros Therapeutics (NASDAQ:KROS) Shares Gap Up to $51.03

Keros Therapeutics, Inc. (NASDAQ:KROS)’s share price gapped up prior to trading on Tuesday . The stock had previously closed at $51.03, but opened at $52.40. Keros Therapeutics shares last traded at $52.03, with a volume of 11,619 shares traded.

Analyst Ratings Changes

KROS has been the subject of a number of analyst reports. Truist Financial reaffirmed a “buy” rating and issued a $100.00 price target on shares of Keros Therapeutics in a report on Tuesday, June 18th. HC Wainwright reaffirmed a “buy” rating and issued a $100.00 price target on shares of Keros Therapeutics in a report on Tuesday, June 18th. Oppenheimer began coverage on Keros Therapeutics in a research report on Tuesday, June 25th. They issued an “outperform” rating and a $102.00 price objective on the stock. Finally, Piper Sandler reiterated an “overweight” rating and issued a $105.00 price objective on shares of Keros Therapeutics in a research report on Wednesday, March 27th. Eight equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the stock presently has a consensus rating of “Buy” and a consensus target price of $88.29.

Keros Therapeutics Stock Up 2.4 %

The business has a 50 day moving average price of $48.27 and a two-hundred day moving average price of $55.20.

Keros Therapeutics (NASDAQ:KROS) last released its earnings results on Wednesday, May 8th. The company reported ($1.21) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.33) by $0.12. The company had revenue of $0.08 million during the quarter. During the same period in the previous year, the business posted ($1.26) earnings per share. The company’s revenue was down 97.3% compared to the same quarter last year. On average, analysts expect that Keros Therapeutics, Inc. will post -4.8 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the business. SG Americas Securities LLC purchased a new position in shares of Keros Therapeutics during the 2nd quarter worth approximately $532,000. Opaleye Management Inc. grew its holdings in shares of Keros Therapeutics by 2.8% during the 1st quarter. Opaleye Management Inc. now owns 367,500 shares of the company’s stock worth $24,328,000 after acquiring an additional 10,000 shares during the period. California State Teachers Retirement System grew its holdings in shares of Keros Therapeutics by 14.0% during the 1st quarter. California State Teachers Retirement System now owns 25,314 shares of the company’s stock worth $1,676,000 after acquiring an additional 3,111 shares during the period. Bayesian Capital Management LP purchased a new position in shares of Keros Therapeutics during the 1st quarter worth approximately $267,000. Finally, Redmile Group LLC purchased a new position in shares of Keros Therapeutics during the 1st quarter worth approximately $36,576,000. Hedge funds and other institutional investors own 71.56% of the company’s stock.

About Keros Therapeutics

Keros Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops and commercializes novel therapeutics for patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta family of proteins in the United States. The company's lead product candidate is KER-050, which is being developed for the treatment of low blood cell counts, or cytopenias, including anemia and thrombocytopenia in patients with myelodysplastic syndromes, as well as in patients with myelofibrosis.